1 / 24

Introduction

Hepatitis B co-infection and Response to Antiretroviral T herapy among HIV-infected Patients in Tanzania Oral abstract # MOAB0101 C. Hawkins , B. Christian, J. Ye, T. Nagu, E. Aris, G. Chalamilla, D. Spiegelman, F, Mugusi, S. Mehta, W. Fawzi.

calais
Download Presentation

Introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hepatitis B co-infection and Response to Antiretroviral Therapy among HIV-infected Patients in TanzaniaOral abstract # MOAB0101 C. Hawkins, B. Christian, J. Ye, T. Nagu, E. Aris, G. Chalamilla, D. Spiegelman, F, Mugusi, S. Mehta, W. Fawzi Presented in part as an Oral presentation at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, Feb 16-19th, 2010

  2. Introduction •  Approximately 6-20% of HIV-infected individuals co-infected with chronic Hepatitis B (HBV) in Sub-Saharan Africa (SSA) • HIV/HBV co-infection associated with • Decreased spontaneous clearance of HBsAg and HBeAg • Faster progression to cirrhosis and hepatocellular carcinoma • Higher liver-related mortality

  3. Introduction • The effect of HIV/HBV co-infection on antiretroviral treatment responses is unclear: • Impaired virologic, clinical and immunologic outcomes (Sheng et al. 2004, Hoffman et al. 2009) • Minimal or no impact of HBV co-infection on ART responses (Hoffman et al. 2008, Konopnicki D et al. 2005, Lincoln et al. 2003) • Very few studies of HIV/HBV co-infection in SSA where both HIV and HBV highly endemic

  4. Objectives • Assess the prevalence of HBV in cohort of HIV-infected adults in urban Tanzania • Compare immunologic and clinical outcomes after ART initiation between HIV mono-infected (HIV) and HIV/HBV co-infected (HIV/HBV) individuals

  5. Methods • Cohort study of adult HIV-infected patients in the Management and Development for Health (MDH) PEPFAR- supported HIV Care and Treatment Program, Tanzania • 18 sites in Dar es Salaam with patients followed in care from November 2004-September 2011

  6. Methods • All patients receive HIV Care and Treatment per National Tanzanian and WHO guidelines • Standard first-line ART • d4T or AZT + 3TC + EFV or NVP • TDF +3TC or FTC+ EFV or NVP preferred for HIV/HBV (2008) • Comprehensive electronic database captures detailed information on clinical diagnoses, antiretroviral therapy, CD4+ cell counts, alanine aminotransferase (ALT), hemoglobin (Hgb), HBsAg, HCV antibody.

  7. Methods • Inclusions: • HBsAg + • Age>15 • ART naïve • Not pregnant at ART initiation • Exclusions: • Co-infection with HBV and chronic HCV* (HCV Ab +) • HBV status unknown * HCV antibody testing was not performed in 53% of study participants

  8. Methods: analysis • Changes in CD4+ cell count over time • generalized estimating equations and robust regression • Incidence of mortality and liver enzyme elevation (hepatotoxicity)* • events/100 person-years • Cox proportional hazards models to examine HBV co-infection in HIV-infected patients in relationship to mortality and hepatotoxicity outcomes *Hepatotoxicity defined as ALT >40 U/l, >3X ULN (120 U/l) and >5X ULN (>200 U/l)

  9. Results: study population Values are median (interquartile) or percentages * variables for which >5% of data missing

  10. Results: study population Values are median (interquartile) or percentages *variables for which >5% of data missing

  11. Results: Risk of mortality *covariates -gender, age, WHO HIV Disease Stage, hemoglobin level (g/dL), CD4+ cell count (cells/μL), ALT greater than 200 IU/L, BMI (kg/m2) , current TB, all at year of initiation as well as year of ARV initiation

  12. Results: Risk of mortality *covariates -gender, age, WHO HIV Disease Stage, hemoglobin level (g/dL), CD4+ cell count (cells/μL), ALT greater than 200 IU/L, BMI (kg/m2) , current TB, all at year of initiation as well as year of ARV initiation

  13. Results: cumulative incidence of all cause mortality

  14. Results: cumulative incidence of all cause mortality

  15. Results: mean changes in CD4+ cell count from baseline *adjusted for gender, age, WHO HIV Disease Stage, hemoglobin level (g/dL), BMI (kg/m2)

  16. Results: overall CD4+ cell count response p<0.01

  17. Results: Risk of hepatotoxicity Patients with the event at baseline were excluded * adjusted for gender, age, WHO HIV Disease Stage, Hemoglobin level (g/dL), CD4+ cell count (cells/μL), BMI (kg/m2) , current TB, NVP use, all at year of initiation, as well as year of ARV initiation

  18. Results: Risk of hepatotoxicity Patients with the event at baseline were excluded * adjusted for gender, age, WHO HIV Disease Stage, Hemoglobin level (g/dL), CD4+ cell count (cells/μL), BMI (kg/m2) , current TB, NVP use, all at year of initiation, as well as year of ARV initiation

  19. Results: Cumulative incidence of moderate-severe hepatotoxicity

  20. Strengths and limitations • Large cohort in SSA examining the effect of HBV on HIV treatment outcomes • Long duration of follow up, comprehensive data on important confounders (TB therapy, alcohol), death • Lack of HBV serologic and virologic data (HBeAg, HBV DNA) • HIV virologic endpoints not assessed • Specific causes of death not examined

  21. Conclusions • Prevalence of HIV/HBV co-infection (6.2%) in this Tanzanian cohort relatively high • Antiretroviral treatment outcomes are impacted by the presence of HBV • Lower CD4+ counts throughout immune restoration • almost 20% higher* risk of mortality • higher risk of moderate-severe hepatotoxicity *p=0.07

  22. Further study • Causes of death –do our results suggest a shift towards more non-AIDS related mortality in SSA? • Mechanisms involved in HBV and HIV-related immune-suppression and any effect on long-term morbidity and mortality? • Etiology of hepatotoxic events and effect (if any) on long-term liver disease progression • The impact of long-term suppressive HBV therapy on these outcomes with agents that are more durable than lamivudine (such as tenofovir)

  23. Acknowledgements • Co-authors and MDH Management • All study participants • HSPH Data managers • Wafaie Fawzi(HSPH), Chloe Thio (JHI), Robert Murphy (NU) This research was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through HRSA under the terms of grant number U51HA02522 through the Harvard School of Public Health The speaker has no conflicts of interest to declare.

  24. Results: risk of mortality by ARV regimen (contains TDF vs. not) * Note, ALL regimens contained LAM

More Related